Background
Methods
Categories | Dengue-confirmed samples (N = 60) | COVID-19-confirmed samples (N = 95)* | Healthy/asymptomatic samples (N = 49) |
---|---|---|---|
Fever day onset, mean (SD) | 5 (1.5) | N/A | N/A |
Age, median (IQR) | 14 (8–22) | 34 (25–46) | 43 (34–52) |
Age | N (%) | ||
Children ≤ 18 years | 35 (58) | 2 (2.1) | 0 (0.0) |
Adults > 18 years | 25 (42) | 78 (82.1) | 49 (100) |
Gender | |||
Male | 28 (47) | 49 (51.6) | 34 (69.4) |
Female | 32 (53) | 31 (32.6) | 15 (30.6) |
Serotype | |||
DENV-1 | 15 (25) | N/A | N/A |
DENV-2 | 15 (25) | N/A | N/A |
DENV-3 | 20 (33) | N/A | N/A |
DENV-4 | 10 (17) | N/A | N/A |
Immunologic status | |||
Primary dengue infection | 10 (17) | N/A | N/A |
Secondary dengue infection | 50 (83) | N/A | N/A |
Presence of anti-dengue antibodies | |||
IgG ( +), IgM ( +) | 21 (35) | N/A | N/A |
IgG ( +), IgM (−) | 16 (27) | N/A | N/A |
IgG (−), IgM ( +) | 14 (23) | N/A | N/A |
IgG (−), IgM (−) | 9 (15) | N/A | N/A |
Results
Specificity (%, 95% CI) | ||
---|---|---|
IgG | IgM | |
Cellex | 100% (95% CI 92.5–100) | 98.3% (95% CI 89.9–99.9) |
Dynamiker | 100% (95% CI 92.5–100) | 100% (95% CI 92.5–100) |
Genbody | 100% (95% CI 92.5–100) | 100% (95% CI 92.5–100) |
Standard diagnostics | 98.3% (95% CI 89.9–99.9) | 98.3% (95% CI 89.9–99.9) |
VivaChek | 100% (95% CI 92.5–100) | 100% (95% CI 92.5–100) |
p-value | 0.404 | 0.555 |
Samples categories | N | Dengue RDT | ||
---|---|---|---|---|
NS1-positive N (%) | IgG-positive N (%) | IgM-positive N (%) | ||
COVID-19 RT-PCR positive | 95 | 1 (1.1) | 2 (2.1) | 2 (2.1) |
COVID-19 IgG RDT positive | 33 | 0 (0.0) | 2 (6.1) | 0 (0.0) |
COVID-19 IgM RDT positive | 19 | 0 (0.0) | 4 (21.1) | 0 (0.0) |